Donepezil: Nursing Drug Guide, Bradycardia & NCLEX Review
Cholinesterase inhibitors can slow the heart and trigger syncope—especially after dose increases—while predictable nausea, vomiting, and diarrhea rise when 5 mg → 10 mg → 23 mg titration is rushed. Verify evening bedtime dosing, never crush the 23 mg tablet, and reconcile anticholinergics and NSAIDs before every dose.
Hold and escalate for symptomatic bradycardia, heart block, or syncope after any dose change. Do not give 10 mg until the patient has taken 5 mg daily for 4–6 weeks, and do not split, crush, or chew the 23 mg tablet. Persistent vomiting with poor intake after escalation can lead to dehydration and falls in older adults with dementia.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the bedtime dose, check heart rate and rhythm, recent dose changes, and GI tolerance. If the patient is dizzy, vomiting repeatedly, or has a new slow pulse after titration, hold donepezil and notify the prescriber or pharmacist—do not crush a 23 mg tablet or jump to 10 mg early.
Most common brand names
Film-coated tablets (5 mg, 10 mg, 23 mg) and orally disintegrating tablets (5 mg, 10 mg) are available. Strength and color differ by product—always verify the milligram strength on the label before administration.
Common U.S. brand names include Aricept and generic donepezil hydrochloride. The 23 mg strength is used for moderate to severe Alzheimer’s disease after adequate time on 10 mg.
Why we give it — Indications
Per U.S. prescribing information, donepezil is indicated for dementia of the Alzheimer’s type. Efficacy has been demonstrated in mild, moderate, and severe disease. It is not a cure—it may slow cognitive and functional decline in some patients.
| Use | Detail |
|---|---|
| Dementia of the Alzheimer’s type | Primary labeled indication across mild, moderate, and severe stages |
| Combination therapy | May be used with memantine per prescriber plan—do not duplicate cholinesterase inhibitors |
| Goals of care | Support cognition and daily function while monitoring cardiac and GI safety—not for acute delirium reversal |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Donepezil is a reversible acetylcholinesterase inhibitor. It increases acetylcholine availability in the brain, which may improve cholinergic neurotransmission in Alzheimer’s disease. Peripheral cholinomimetic effects explain predictable GI symptoms and possible vagotonic cardiac effects (bradycardia, heart block).
Dosing overview
Take in the evening at bedtime, with or without food. Steady state is reached in about 15 days—untoward effects may be influenced by the rate of dose escalation.
| Scenario | Dose adjustment (labeling) |
|---|---|
| Renal impairment | In moderate to severe renal impairment (ClC <18 mL/min/1.73 m²), clearance did not differ from matched healthy subjects in a small study—no dedicated adjustment stated; monitor clinically |
| Hepatic impairment | Stable alcoholic cirrhosis: clearance decreased about 20%—use caution; no specific dose provided |
| Lower body weight (<55 kg) | On 23 mg/day, more nausea, vomiting, and weight loss than patients ≥55 kg in controlled trial |
| Pediatrics | Safety and effectiveness in children not established |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: If a dose is missed, take when remembered unless almost time for the next bedtime dose—do not double doses. Repeated extra doses increase cholinergic adverse effects and overdose risk.
Before you give it — Safety check
Pretreatment checks
- Complete medication reconciliation—no second cholinesterase inhibitor; review anticholinergics (diphenhydramine, bladder antispasmodics)
- Confirm allergy history: hypersensitivity to donepezil or piperidine derivatives
- Baseline and pre-dose heart rate and rhythm; history of syncope, heart block, or asthma/COPD
- Review NSAID or aspirin use and ulcer history—GI bleeding risk increases at 23 mg vs 10 mg in labeling
- Verify correct strength (5, 10, or 23 mg) and that titration intervals are met before increasing dose
- Assess swallowing for tablets vs ODT; fall-risk plan if dizziness reported
Contraindications
- Known hypersensitivity to donepezil hydrochloride or piperidine derivatives
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Anticholinergics | Opposing mechanisms—may reduce benefit and worsen cognition, retention, constipation | Reconcile burden; notify prescriber/pharmacist before combining |
| Other cholinesterase inhibitors / cholinomimetics | Synergistic cholinergic effects with succinylcholine, bethanechol, similar agents | Hold duplicates; flag anesthesia and perioperative plans to surgical team |
| NSAIDs (ibuprofen, aspirin) | Increased gastric acid secretion; monitor for GI bleeding—higher rates at 23 mg in trial | Teach bleeding signs; coordinate gastroprotection per prescriber |
| CYP3A4 / CYP2D6 inhibitors (e.g., ketoconazole, quinidine) | May increase donepezil concentrations | Pharmacy review when new inhibitors start; watch for GI and cardiac effects |
| CYP inducers (phenytoin, carbamazepine, rifampin) | May increase elimination of donepezil | Notify prescriber if cognition changes after starting inducers |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral route: Give once daily in the evening just prior to retiring per labeling. May take with or without food.
- Film-coated tablets: swallow whole with water unless using ODT formulation
- ODT: allow to dissolve on tongue, then follow with water
- 23 mg tablet: administer whole only—do not split, crush, or chew (may increase absorption rate)
- Use medication administration five-rights; independent double-check on strength changes
As a cholinesterase inhibitor, donepezil may exaggerate succinylcholine-type muscle relaxation during anesthesia. Coordinate hold timing with anesthesia and surgical teams per institutional protocol—do not stop or restart without prescriber direction.
Expected therapeutic response
- Gradual stabilization or modest improvement in cognition, communication, or daily function over weeks to months—not immediate
- Mild, transient GI effects (nausea, diarrhea) may occur early and often resolve without dose change
- Absence of new syncope, bradycardia, or progressive weight loss after dose changes
- Caregiver reports of safer participation in ADLs when therapy is tolerated
Red flags — Stop and act
Escalate immediately for cardiac symptoms, cholinergic crisis, or dangerous administration errors.
- Bradycardia, heart block, or syncope—especially after dose increase; hold dose and obtain cardiac evaluation per protocol
- Persistent vomiting, dehydration, or inability to take oral fluids after titration to 10 mg or 23 mg
- GI bleeding—melena, hematemesis, or symptomatic anemia in patients on NSAIDs or ulcer history
- New seizures—may be drug-related or disease-related; urgent neurological review
- Suspected overdose—salivation, sweating, bradycardia, hypotension, respiratory depression, collapse, convulsions
- Crushed or split 23 mg tablet given—treat as medication error; monitor for exaggerated cholinergic effects
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Nausea, diarrhea, vomiting | More common at 10 mg than 5 mg; markedly higher at 23 mg vs 10 mg (nausea 11.8% vs 3.4% in one trial); faster 1-week titration raised nausea to 19% vs 6% with 6-week titration | Hold escalation; notify prescriber; monitor intake and electrolytes |
| Insomnia, muscle cramps, fatigue, anorexia | Common cholinomimetic effects at ≥5% on 10 mg/day and twice placebo rate | Document; differentiate from disease progression; support sleep hygiene |
| Syncope / bradycardia | Syncope 2% vs 1% placebo in mild–moderate trials; bradycardia reported | Hold dose; cardiac monitoring; fall precautions |
| Weight loss | More frequent at 23 mg; ≥7% body-weight loss in 8.4% on 23 mg vs 4.9% on 10 mg | Weekly weights; dietitian referral; review continued 23 mg need |
| Confusion, agitation, hallucinations | Postmarketing reports; may overlap with Alzheimer’s behavioral symptoms | Assess delirium triggers; avoid stacking sedating anticholinergics |
| Constipation | GI cholinergic effects; monitor with anticholinergic co-meds | Bowel regimen; hydration; retention assessment |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdosage with cholinesterase inhibitors can cause cholinergic crisis: severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse, and convulsions. Increasing muscle weakness may involve respiratory muscles.
Management (labeling)
- General supportive measures; contact poison control/toxicology per facility protocol
- Tertiary anticholinergics such as atropine may be used as an antidote
- IV atropine sulfate titrated to effect: initial 1.0–2.0 mg IV, then repeat based on clinical response
- Monitor airway, heart rate, blood pressure, and neuromuscular function
- Dialysis removal not known—do not rely on dialysis alone
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for suspected overdose—especially with bradycardia, respiratory depression, or collapse.
Look-alike / sound-alike and error prevention
- Donepezil vs galantamine, rivastigmine, memantine—read back full generic name; do not substitute another dementia drug without prescriber order
- 5 mg vs 10 mg vs 23 mg—color and debossing differ by brand; independent double-check after titration orders
- Bedtime HS vs morning—giving in the morning may worsen GI sleep disruption; follow labeled evening timing
- Crushing 23 mg tablets—never crush for feeding tubes without pharmacy conversion; label prohibits split/crush/chew
- Early 10 mg—common error at week 1–2; verify patient completed 4–6 weeks on 5 mg
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Pre-dose pulse check | Document HR and symptoms before evening dose for 48–72 h after any titration |
| Titration calendar | Flag MAR when 10 mg is due only after 4–6 weeks on 5 mg; 23 mg only after 3 months on 10 mg |
| GI day 1–14 | Expect mild nausea—escalate if vomiting prevents fluids or weight drops ≥7% |
| Commonly missed | Home diphenhydramine plus donepezil; duplicate cholinesterase patch; NSAID without GI plan |
| Ask pharmacy when | Feeding-tube administration, CYP inhibitor added, or anesthesia hold timing unclear |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (typical patient) | Mean trial age ~73 years; syncope and GI effects more clinically consequential—fall and aspiration precautions |
| Body weight <55 kg | Higher nausea, vomiting, weight loss, and withdrawals on 23 mg—closer monitoring |
| Cardiac conduction disease | Bradycardia or heart block may occur with or without known conduction abnormalities |
| Asthma / COPD | Prescribe with care because of cholinomimetic pulmonary actions |
| Peptic ulcer / NSAID users | Monitor for occult or active GI bleeding; increased bleeding rates at 23 mg in trial |
| Pregnancy | Pregnancy Category C—use only if potential benefit justifies fetal risk; adequate human studies not available |
| Lactation | Not known if excreted in human milk—caution when administered to a nursing woman |
| Pediatrics | Safety and effectiveness not established |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Heart rate, rhythm, blood pressure, and syncope or dizziness—especially after titration
- GI tolerance: nausea, vomiting, diarrhea, oral intake, and weight trend
- Mental status and behavior—separate drug effects from Alzheimer’s progression
- Signs of GI bleeding in patients on NSAIDs or ulcer history
- Respiratory status in asthma/COPD; urinary symptoms (cholinomimetics may cause bladder outflow obstruction)
Document
- Strength, formulation (tablet vs ODT), time given (bedtime), and titration milestone dates
- Hold events with prescriber/pharmacist notification and cardiac assessment results
- Caregiver teaching on bedtime dosing, swallowing whole 23 mg tablets, and when to call
- Perioperative hold/restart instructions from anesthesia or prescriber
Patient teaching
- Take once daily at bedtime—do not take extra tablets if a dose is missed
- Swallow the 23 mg tablet whole—do not crush or chew
- Mild nausea may improve with time—call if vomiting prevents drinking fluids
- Report dizziness, fainting, slow heartbeat, black stools, or severe abdominal pain immediately
- Keep a list of all medicines—including allergy and sleep aids—and share with every clinician
- Caregivers should supervise evening dosing and watch for falls after dose increases
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Known hypersensitivity to donepezil or piperidine derivatives
- Symptomatic bradycardia, suspected heart block, or syncope after dosing
- Persistent vomiting, inability to maintain hydration, or prescriber order to stop during GI intolerance
- Order for 10 mg before patient completed 4–6 weeks on 5 mg, or 23 mg before 3 months on 10 mg
- 23 mg tablet is broken, crushed, or wrong formulation for swallow status
- Active GI bleeding or hemodynamic instability until prescriber directs plan
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
On memory-care and geriatric units, donepezil is often continued from home without a titration calendar. Pair bedtime administration checks with cardiac and GI surveillance after every dose change.
1. Check-before-you-give protocol
- Right patient, drug, strength (5/10/23 mg), route, and bedtime time
- Titration interval met; 23 mg tablet intact
- Heart rate and symptom screen; no active vomiting or syncope
- No duplicate cholinesterase inhibitor on MAR
2. High-alert and safety badge
Not a universal high-alert drug, but bradycardia/syncope and cholinergic crisis can be life-threateningTreat dose-escalation errors and 23 mg crushing like high-risk events: independent verification, prescriber notification, and enhanced monitoring.
3. Clinical workflow: hold and question rules
- If HR below facility threshold or patient reports fainting, hold and obtain cardiac review before next dose
- If 10 mg starts before week 4 on 5 mg, hold and clarify with pharmacy
- If NSAID started without GI plan on 23 mg, request prescriber/pharmacy review
4. Critical teach-back questions
- “When do you take this medicine?” (Once daily at bedtime.)
- “What should you do if you feel faint or vomit repeatedly?” (Hold the dose and contact the care team immediately.)
5. Care coordination
Pharmacist: Titration scheduling, interaction review, feeding-tube formulation, overdose antidote guidance
Prescriber / memory-care team: Cognition goals, hold parameters, anesthesia planning, switch to memantine or stop therapy when not tolerated
🧠 Quick mental checklist
- Bedtime dose with correct mg strength?
- Titration interval met before 10 mg or 23 mg?
- Heart rate acceptable and no syncope?
- GI symptoms manageable and patient drinking fluids?
- 23 mg tablet whole—not crushed?
Donepezil NCLEX practice questions
Practice NCLEX-style clinical judgment practice for donepezil with a tabbed memory-care case (MAR, labs, vitals, nursing notes), then priority action, cholinergic and cardiac cue recognition, deterioration trends, documentation cloze, overdose judgment, and matrix urgency—recognize cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Donepezil 5 mg PO at bedtime — day 28 (completed 4 weeks at 5 mg)
- New order: donepezil 10 mg PO at bedtime starting tonight (day 29)
- Ibuprofen 400 mg PO TID with meals — day 4 for knee pain
- Diphenhydramine 25 mg PO at bedtime PRN — given last night for restlessness
- Memantine 10 mg PO every morning — unchanged
- Na 138 mmol/L, K 3.9 mmol/L, Cl 102 mmol/L, CO2 24 mmol/L
- BUN 22 mg/dL, creatinine 1.0 mg/dL (baseline 0.9)
- Hgb 12.8 g/dL (baseline 13.4 one month ago)
- Not specified in the reviewed prescribing information for routine serum donepezil levels
- Yesterday bedtime (on 5 mg): HR 76, BP 128/70, RR 16
- Today 0800: HR 68, BP 118/68; reports mild nausea
- Today 1600 (pre–10 mg dose): HR 52, BP 102/60; dizzy when standing
- Intake 450 mL oral; two episodes of vomiting after lunch
- 82-year-old with moderate Alzheimer’s disease; ambulates with walker; fall precaution
- Caregiver states patient was stable on 5 mg; prescriber increased to 10 mg today
- Near-syncope in hallway at 1545—supported to chair; no injury
- Evening MAR lists 10 mg tablet available; pharmacy label states do not crush
Answer key & rationale
Frequently asked questions
Why are bradycardia and syncope the main nursing concerns with donepezil?
Cholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, manifesting as bradycardia or heart block. Syncopal episodes have been reported with donepezil. Nurses should check heart rate and rhythm before doses, especially after dose increases.
When should nurses hold donepezil?
Hold for hypersensitivity; symptomatic bradycardia, heart block, or syncope; persistent vomiting with dehydration; suspected GI bleeding; unsafe titration orders; crushed 23 mg tablets; or prescriber direction to discontinue for intolerance.
How should donepezil be titrated?
Start 5 mg once daily at bedtime. Give 10 mg only after 4–6 weeks on 5 mg. Give 23 mg only after at least 3 months on 10 mg when prescribed for moderate to severe Alzheimer’s disease.
What is the antidote for donepezil overdose?
Cholinergic crisis may require supportive care and IV atropine sulfate titrated to effect (initial 1.0–2.0 mg IV) per U.S. prescribing information. Contact poison control/toxicology per facility protocol.
Can donepezil be taken with anticholinergic medicines?
Cholinesterase inhibitors may interfere with anticholinergic activity. Reconcile anticholinergic burden and question combinations that worsen cognition, retention, or constipation in older adults.
References
-
U.S. National Library of Medicine. ARICEPT (donepezil hydrochloride) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d15879-3883-4963-9c93-73d5251484fa
-
National Library of Medicine. MedlinePlus: Donepezil.https://medlineplus.gov/druginfo/meds/a697009.html
-
Drugs and Lactation Database (LactMed). Donepezil. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501509/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.